.webp&w=384&q=75){kind=logo}
S3V to Launch Affordable Made-in-India TAVR System
S3V Vascular Technologies recently reached a major milestone in Indian medical innovation. They announced plans to move their indigenous TAVR system India into preclinical evaluation. This phase will validate the safety and design performance of the balloon-expandable device. Consequently, the company hopes for a commercial launch within the next 18 months.
The Impact of the indigenous TAVR system India
Transcatheter Aortic Valve Replacement (TAVR) offers a minimally invasive alternative for severe aortic stenosis. Traditionally, patients required open-heart surgery for valve issues. However, clinicians can now replace the valve via a catheter. This method significantly reduces recovery time for high-risk or elderly patients. Furthermore, domestic innovation ensures that the technology meets local clinical needs effectively.
Addressing Accessibility and Cost Challenges
Currently, India performs only 4,000 TAVR procedures annually. Nevertheless, the clinical need exceeds 50,000 cases each year. High costs of imported devices create a significant barrier for many patients. Imported systems usually cost between ₹13 lakh and ₹23 lakh. Therefore, S3V aims to democratize care by providing a high-quality, local alternative. This shift could transform cardiac care delivery across the country.
Frequently Asked Questions
Q1: What is the main benefit of the S3V TAVR system?
A1: It aims to provide a high-quality, affordable local alternative to expensive imported heart valves, increasing accessibility for Indian patients.
Q2: When will the new TAVR system be available?
A2: S3V plans to launch the device commercially within 12 to 18 months, pending successful trials and regulatory approvals.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
- S3V Vascular Tech to advance Made in India valve replacement system topreclinical stage - ETHealthworld
- Cardiovascular Research: Clinical Outcomes of Balloon-Expandable TAVR Systems
- Indian Journal of Cardiology: Addressing the Cost of Structural Heart Interventions
More from MedShots Daily
S3V Vascular Technologies moves its indigenous TAVR system into preclinical trials to lower costs and improve access to cardiac care for Indian patients....
last month
A CSTEP study in Bengaluru reveals that low-cost air quality sensors require local calibration and frequent checks to ensure reliable data for health....
Today
A review of deep learning-based AI in pelvic malignancy segmentation, highlighting its potential to improve radiotherapy accuracy and workflow efficiency....
Today
New echocardiography-assisted ductus venosus stenting technique for premature neonates with infracardiac TAPVC provides a vital bridge to surgical repair....
Today
AIIMS Delhi researchers find deoxycholic acid (DCA) from gut bacteria protects against osteoporosis by boosting bone formation and reducing inflammation....
Today
New research highlights the vital role of mitochondrial enzymes Idp1 and Pos5 in maintaining the NADPH pool required for Coenzyme Q biosynthesis....
Today